meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
1
mCRC - 2nd line (L2)
3
endometrial cancer
1
esophageal cancer (EC)
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">pembrolizumab based treatment</span>
<span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
AE (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
AE leading to death (grade 5) (1)
Alopecia TRAE (grade 3-4) (1)
Colitis TRAE (grade 3-4) (1)
Hypophysitis TRAE (grade 3-4) (1)
Adrenal insufficiency TRAE (grade 3-4) (1)
Severe skin reaction TRAE (grade 3-4) (1)
Pancreatitis TRAE (grade 3-4) (1)
Nephritis TRAE (grade 3-4) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Myositis TRAE (grade 3-4) (1)
Increased ALT TRAE (grade 3-4) (1)
Increase AST TRAE (grade 3-4) (1)
Hepatitis TRAE (grade 3-4) (1)
Myocarditis TRAE (grade 3-4) (1)
Peripheral neuropathy TRAE (grade 3-4) (1)
Mucosal inflammation TRAE (grade 3-4) (1)
Stomatitis TRAE (grade 3-4) (1)
Epistaxis TRAE (grade 3-4) (1)
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1)
Infusion-related reactions TRAE (grade 3-4) (1)
Dizziness TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Peripheral sensory neuropathy TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Hyperthyroidism TRAE (grade 3-4) (1)
Thyroiditis TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Arthralgia TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Diabetes TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Leucopenia TRAE (grade 3-4) (1)
Diarrhoea AE (grade 3-4) (1)
Increased ALT AE (grade 3-4) (1)
Increase AST AE (grade 3-4) (1)
Pyrexia AE (grade 3-4) (1)
Weight decreased AE (grade 3-4) (1)
Pruritus AE (grade 3-4) (1)
Rash AE (grade 3-4) (1)
Nausea AE (grade 3-4) (1)
Vomiting AE (grade 3-4) (1)
Constipation AE (grade 3-4) (1)
Abdominal pain AE (grade 3-4) (1)
Fatigue AE (grade 3-4) (1)
Asthenia AE (grade 3-4) (1)
Headache AE (grade 3-4) (1)
Decreased appetite AE (grade 3-4) (1)
Cough AE (grade 3-4) (1)
Hypertension AE (grade 3-4) (1)
Hypothyroidism AE (grade 3-4) (1)
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) (1)
Arthralgia AE (grade 3-4) (1)
Stomatitis AE (grade 3-4) (1)
Mucosal inflammation AE (grade 3-4) (1)
Anaemia AE (grade 3-4) (1)
Dyspepsia AE (grade 3-4) (1)
Neutropenia AE (grade 3-4) (1)
Dizziness AE (grade 3-4) (1)
Dry skin AE (grade 3-4) (1)
Peripheral oedema AE (grade 3-4) (1)
Epistaxis AE (grade 3-4) (1)
Peripheral neuropathy AE (grade 3-4) (1)
Alopecia AE (grade 3-4) (1)
Dyspnoea AE (grade 3-4) (1)
Back pain AE (grade 3-4) (1)
Peripheral sensory neuropathy AE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
Standard of Care (SoC)
pembrolizumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
Standard of Care (SoC)
pembrolizumab alone
Standard of Care (SoC)
---
NA
pembrolizumab alone
NA
---
pathologies: 137 - treatments: 359,575,577,576,869
result logic
×
Study list
